Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652754 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
A Phase 1 study of Diabetic Foot Ulcers, sponsored by Xequel Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT02652754 is a Phase 1 study of Diabetic Foot Ulcers that has completed, run by Xequel Bio. The registered enrollment target is 16 participants, below the 233-participant average among 12 other Diabetic Foot Ulcers trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02652754, a Phase 1 study of Diabetic Foot Ulcers, has completed, sponsored by Xequel Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
Conditions Studied
Interventions
- DRUG Granexin® gel
Study Locations (3)
Georgia
- Aiyan Diabetes Center - Augusta
South Carolina
- Spartanburg Regional Healthcare System - Spartanburg
Virginia
- Salem VA Medical Center - Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652754
The ClinicalTrials.gov registry entry for NCT02652754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 12 other Diabetic Foot Ulcers trials with a reported enrollment target (93% lower). The listed sponsor is Xequel Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Foot Ulcers appearing as the primary indexed condition, and to 1 intervention - of which Granexin® gel is the first listed.
NCT02652754 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT02652754 about?
NCT02652754 is a clinical study titled "Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers". The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
What is the current status of trial NCT02652754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-09. Estimated completion is 2018-05.
What conditions does trial NCT02652754 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcers.
What interventions are being tested in trial NCT02652754?
The interventions under investigation include: Granexin® gel (DRUG).
Who is sponsoring clinical trial NCT02652754?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02652754 being conducted?
This trial has 3 study locations across Georgia, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wound Healing Endpoint and Recurrence
ACTIVE NOT RECRUITING · Phase 1
-
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3
COMPLETED · Phase 2
-
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
COMPLETED
-
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
COMPLETED · Phase 3
-
Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.